Shernan Holtan: A positive but negative GVHD prophylaxis story with JAK2i
Shernan Holtan, Chief of the Blood and Marrow Transplant Program at Roswell Park, shared on LinkedIn about recent paper by Joseph A Pidala et al., titled “JAK2/mTOR Inhibition Fails to Prevent Acute GVHD Despite Reduced Th1/Th17 cells: Final Phase II Trial Results” published on Blood.
Authors: Joseph A Pidala, Shernan G Holtan, Kelly Walton, Jongphil Kim, Biwei Cao, Hany Elmariah, Asmita Mishra, Nelli Bejanyan, Taiga Nishihori, Farhad Khimani, Lia E Perez, Rawan G Faramand, Marco L. Davila, Shannon McSain, Jordan Pleskow, Jeffrey Baron, Claudio Anasetti, Carlos M Moran Segura, Daniel J Weisdorf, Bruce R Blazar, Jeffrey S. Miller, Veronika Bachanova, Najla El Jurdi, Brian C Betts
“A positive but negative GVHD prophylaxis story with JAK2i.
Pacritinib reduced STAT3 in CD4 T cells (met primary endpoint!) and reduced Th1/Th17 cells in the blood at day +21.
However, this biological efficacy did not translate to patient benefit. Clinically, JAK2i did not prevent GVHD.
Humbling.”
Source: Shernan Holtan/LinkedIn
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023